Section
FGF18 produced by stromal fibroblasts promotes AML progression via FGFR3-mediated AKT-mTOR signaling, forming a feed-forward loop that impairs CD8+ T-cell immunity. Neutralizing FGF18 synergizes with PD-1 blockade, suggesting a novel therap
This study demonstrates that one-stage assay (OSA) factor VIII activity better reflects the functional enhancement of AAV-derived FVIII in hemophilia A gene therapy, offering superior prediction of bleeding phenotype compared to chromogenic
This study evaluates how clonal hematopoiesis of indeterminate potential (CHIP) and pre-treatment neutropenia affect clinical outcomes and toxicities in patients undergoing CAR-T therapy for hematologic cancers, revealing nuanced risks for
Emerging therapies have revolutionized first-line treatment in large B-cell lymphoma, but inconsistent trial designs and biomarker use create complexity. Harmonized strategies integrating biomarkers, pooled data, AI, and regulatory collabor
This retrospective study evaluates survival outcomes and risk factors associated with allogeneic hematopoietic cell transplantation in young adults (18-40 years) with myelodysplastic syndrome, revealing encouraging survival rates and highli
This analysis of BMT CTN 1202 reveals that rabbit ATG exposure influences survival, relapse, and immune recovery after T-replete hematopoietic cell transplantation, advocating for model-based dosing to optimize outcomes.
This review synthesizes evidence from the ELEVATE trial on adding cusatuzumab, a CD70-targeting antibody, to venetoclax with or without azacitidine in unfit AML patients, highlighting therapeutic potential, safety concerns, and translationa
This review synthesizes emerging evidence comparing high-dose anti-CD25 (without methotrexate) versus low-dose anti-CD25 (with methotrexate) strategies for GVHD prophylaxis in haplo-HSCT, highlighting improved acute GVHD control and GRFS wi
CHIP and pre-treatment neutropenia do not significantly affect survival or main toxicities in CAR-T therapy for hematologic cancers but may predict specific inflammatory toxicities, indicating distinct risk profiles for patient management.
This article explores novel therapeutic strategies in acute myeloid leukemia by combining PI3K inhibitors with EZH1/2 dual inhibitors to overcome epigenetic resistance mechanisms in leukemic stem cells, offering promising pathways to preven
A phase 1b/2 study evaluating zilovertamab combined with ibrutinib in relapsed/refractory CLL reveals safety, mechanistic inhibition of ROR1 signaling pathways, and a potential efficacy signal in del(17p) patients warranting further studies
The GLOW phase III trial demonstrates that fixed-duration ibrutinib-venetoclax provides superior overall survival, progression-free survival, and safety compared to chlorambucil-obinutuzumab in older/comorbid CLL patients, with durable dise
This study presents a comprehensive single-cell RNA-sequencing atlas of CTCL, identifying oncogenic transcriptional programs and immune microenvironment features that offer new therapeutic targets for advanced-stage disease.
This study reveals that syndecan-4 shedding exacerbates deep vein thrombosis by promoting Piezo1-dependent endothelial-mesenchymal transition, with quercetin showing promise as a novel therapeutic Piezo1 inhibitor.
This study assesses medium-term cognitive changes in CNS lymphoma patients treated with CAR T-cell therapy, revealing cognitive stability or improvement up to 12 months post-treatment, despite initial neurotoxicity risks.
A pooled analysis of REPRIME-FIL and CART-SIE studies shows CAR T-cell therapy significantly improves overall survival in relapsed/refractory primary mediastinal B-cell lymphoma compared to traditional salvage treatments including ASCT.
BCMA-targeted CAR T-cell therapy demonstrates substantial efficacy and an acceptable safety profile as a salvage option for relapsed/refractory multiple myeloma patients after failure of prior anti-GPRC5D CAR T-cell treatments.
A phase 1 trial demonstrates that venetoclax combined with inotuzumab ozogamicin is safe and highly effective in producing durable MRD-negative remissions in relapsed/refractory B-cell ALL and lymphoblastic lymphoma.
Hematologists and oncologists possess critical skills to address hematologic complications of acute radiation syndrome and are essential in bolstering mass casualty radiation response, utilizing existing resources and infrastructure for eff
A phase 2 trial demonstrates that adding venetoclax to pediatric chemotherapy regimens in adolescents and adults with newly diagnosed Philadelphia chromosome-negative ALL significantly improves MRD negativity and survival with manageable to
